Aspen to list shares on A2X from April
‘We will retain our primary listing on the JSE and our issued share capital will be unaffected by the secondary listing,’ CEO Stephen Saad says
JSE-listed Aspen Pharmacare, whose market value has declined 35% since March 7, said on Monday its shares would start trading on SA’s A2X exchange from April. “We continually strive to identify ways to increase value for our shareholders and the complementary A2X listing offers investors trading benefits while simultaneously providing the prospect of increasing our shareholder base,” said Aspen CEO Stephen Saad. “We will retain our primary listing on the JSE and our issued share capital will be unaffected by the secondary listing,” Saad said. Aspen’s shares, which have been rocked by debt concerns, were 0.1% up at R91.20 on Monday morning. Earlier in March, the global pharmaceutical company’s shares plunged as much as 51% to R68.99 in just two hours after Aspen said in an earnings report that borrowings, net of cash, had increased by R6.7bn to R53.5bn. Prior to releasing its results, Aspen’s shares were at R141.15. Meanwhile, winning over Aspen is another step forward for A2X, which...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.